ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

Authors	KOESSLER T. ALSINA M. ARNOLD D. BEN-AHARON I. COLLIENNE M. LUTZ M. P. NEUZILLET C. OBERMANNOVÁ Radka PEETERS M. SCLAFANI F. SMYTH E. VALLE J. W. WAGNER A. D. WYRWICZ L. FONTANA E. MOEHLER M.
Year of publication	2022
Type	Article in Periodical
Magazine / Source	ESMO OPEN
MU Faculty or unit	Faculty of Medicine
Citation
Web	https://www.sciencedirect.com/science/article/pii/S2059702922000126?via%3Dihub
Doi	http://dx.doi.org/10.1016/j.esmoop.2022.100392
Keywords	oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer
Description	There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.